Contact Us

We are committed to the professional and patient communities we serve. In the spirit of this commitment, we invite ongoing feedback and dialogue.

Corporate Information:

Lantheus Medical Imaging
331 Treble Cove Rd.
N. Billerica, MA 01862

Phone: 1-800-362-2668
(for Massachusetts and International, call 978-667-9531)

Customer Service/Order DEFINITY®:

Call Toll-Free:
800-299-3431
Fax:
978-436-7501
Monday-Thursday  7:30 a.m. to 8:00 p.m. ET
Friday7:30 a.m. to 7:00 p.m. ET

 

DEFINITY® Reimbursement Support:

Call Toll-Free:
800-362-2668 x7995

For reimbursement regarding DEFINITY®

Lantheus Medical Imaging cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely and third party payment for medical products and services is affected by numerous factors.  It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding and payment information.

Adverse Event and Product Quality Complaint Reports:

i3 Drug Safety is the pharmacovigilance partner of Lantheus Medical Imaging.

Call:

United States

1-800-343-7851

  • Press Option 2 for Adverse Events
  • Press Option 3 for Product Quality Complaints

Fax: 1-866-880-9343

Outside US/Canada

978-667-9531

  • Press Option 2 for Adverse Events
  • Press Option 3 for Product Quality Complaints

Fax: 734-929-6688

E-Mail: i3drugsafetypv@i3drugsafety.com

Medical Information:

For adverse events and product quality complaints, please use contact information above.
Call Toll-Free:

1-800-343-7851
  • Press Option 4 for: Medical Information

Fax: 1-978-671-8736
Monday-Friday 8:30 a.m. to 4:30 p.m. ET

Sales

If you would like a sales representative to contact you, please complete the form below.

Contact Form

* Please complete the required fields below

* Salutation
* First Name
* Last Name

* Professional Degree

MD DO PhD
PharmD RPh PA
NP RDMS RN
BS/BA MA MBA
Other    
* Facility
* Address
* City
* State
* ZIP
* Telephone
Fax
* E-mail
* I am interested in the following (check all that apply):
* Please enter your questions or comments below.
Do you wish to be added to our email list to receive additional information about DEFINITY®?

How we will use this information:

Lantheus Medical Imaging may collect data from you that you provide to us voluntarily, such as your name, postal address, e-mail address, telephone number and other personal information, such as your education level, professional affiliation, marital status, or personal medical information. If you provide us with these data, you agree that we may contact you to provide you with information we believe may be of interest to you.

Your information may be provided to other parties that Lantheus Medical Imaging is working with in order to help develop programs and provide services that may be of interest to you or for processing, mailing, and/or Internet-based delivery purposes within authorized Lantheus Medical Imaging personnel in other countries. At all times, personal data are treated confidentially.

If at any time you do not wish us to contact you or if you have any questions concerning our privacy practices, please feel free to contact us at bi.webadmin@lantheus.com.

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

CONTRAINDICATIONS

Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING: Serious Cardiopulmonary Reactions 

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
  • In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
  • Always have resuscitation equipment and trained personnel readily available.


In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please See Full Prescribing Information and Letter to Healthcare Providers.

HOME